New drug KAI-1678 tested for shingles nerve pain relief
NCT ID NCT01106716
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tested whether a single dose of KAI-1678 can reduce pain in people with postherpetic neuralgia, a type of nerve pain that lingers after shingles. 23 adults with stable pain levels received either KAI-1678, a placebo, or lidocaine. The main goal was to see if pain intensity dropped within 6 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KAI-1678
- What this could lead to
- If it works, this could point toward a new treatment option for nerve pain after shingles.
- What could go wrong
- This is a very small Phase 2 trial with only 23 participants, so results may not be reliable or apply to everyone. The drug may not reduce pain better than placebo or lidocaine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTHERPETIC NEURALGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Sydney, New South Wales, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New gel promises shingles pain relief in minutes
- Can nerve zapping predict who gets pain relief from shingles?
- New hope for shingles pain sufferers: drug trial underway
- New drug shows promise for shingles nerve pain
- Shingles pain relief showdown: nerve block vs radiofrequency
- Zapping away shingles pain: new trial tests pulsed radiofrequency